The KRAS-G12C inhibitor: activity and resistance - Nature
2021年9月1日 · Although it has long been deemed “undruggable”, with the development of drugs specifically binding the KRAS-G12C mutant protein, clinical trials that directly inhibit oncogenic …
Targeting KRAS in cancer - Nature Medicine
2024年4月18日 · The first successes occurred with allele-specific targeting of KRAS p.Gly12Cys (G12C) in non-small cell lung cancer, resulting in regulatory approval of two agents—sotorasib …
KRAS - The New England Journal of Medicine
2020年9月20日 · We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once daily. The …
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
2021年6月4日 · Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …
Advances in KRAS G12C-Mutated NSCLC: Key Insights from ELCC …
5 天之前 · The event brought together experts to discuss groundbreaking advancements in lung cancer research and treatment, shaping the future of patient care. Advances in KRAS G12C …
KRAS G12C Inhibitors: New Drugs, A New Hope - Journal of …
In this issue of the Journal of Thoracic Oncology, Zhou et al. 8 present safety and efficacy data of a new KRAS G12C inhibitor in NSCLC, IBI351.
The path to the clinic: a comprehensive review on direct KRAS
Analyzing amino acid-specific KRAS mutations in the three cancer types responsible for most KRAS mutations, the most common KRAS mutation in NSCLC adenocarcinoma subtype is …
Advances in the treatment of KRASG12C mutant non–small cell …
3 天之前 · Kirsten rat sarcoma (KRAS) is one of the most frequently mutated oncogenic drivers in metastatic non–small cell lung cancer (NSCLC). The development of selective, covalent KRAS …
Distinct Clinical and Treatment Profiles of KRAS G12D and G12C …
3 天之前 · KRAS G12D and G12C mutations exhibit distinct biological and clinical characteristics that influence treatment response in patients with metastatic non-small-cell lung cancer …
RASON promotes KRAS
2025年3月25日 · Background KRAS is the most frequently mutated oncogene in human cancers, with KRAS G12C being a prevalent driver mutation in 12–13% non-small cell lung cancer …